Business Wire

Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Oral CDK2 Inhibitor at San Antonio Breast Cancer Symposium

WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
Nature

Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs)

A key feature of cancer is the disruption of cell cycle regulation, which is characterized by the selective and abnormal activation of cyclin-dependent kinases (CDKs). Consequently, targeting CDKs via ...
Medical Xpress

Scientists propose CDK2 enzyme as new target for cancer therapy

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted ...
Nasdaq

Monte Rosa Therapeutics Presents Promising Preclinical Data on CDK2 Molecular Glue Degrader MRT-51443 for HR-Positive/HER2-Negative Breast Cancer at AACR Annual Meeting 2025

CDK2 molecular glue degrader MRT-51443 shows enhanced tumor regression and delayed resistance in breast cancer models, surpassing standard treatments. Details regarding the clinical development ...